Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about DRUG, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Technetium Tc-99m Albumin Aggregated | Carcinoma | Phase 4 · NCT05848947 | Completed |
| ASI-02 | Right-To-Left Shunt | Phase 3 · NCT06938347 | Recruiting |
| BMB-101 | Absence Epilepsy | Phase 2 · NCT06401538 | Recruiting |
| BC-101 | Nasolabial Fold Wrinkles | Phase 1 · NCT05162326 | Not yet recruiting |
| Anti-PD-1 Antibody/IL-18 Variant Immunoc | Advanced Solid Tumors | Phase 1 · NCT06779851 | Terminated |
| YB-1113 | POI | Phase 1 · NCT05494723 | Not yet recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
DRUG holds $307.8M in cash and short-term investments and burns about $6.2M/quarter from operations, an estimated runway of 149.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 15 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DRUG files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Ian McDonald | 5%+ holder (13D) | 1,396,665 | 30.87% | 2024-11-04 |
| Jupiter Topco LLC | Institution (13F) | 1,349,107 | 29.82% | 2026-06-30 |
| JANUS HENDERSON GROUP PLC | Institution (13G, 5%+) | 1,284,324 | 28.39% | 2026-03-31 |
| Cormorant Asset Management, LP Former 10% Owner |
Insider | 900,000 | 19.89% | 2026-06-30 |
| Blackrock Inc. | Institution (13F) | 686,184 | 15.17% | 2026-06-30 |
| Vivo Capital, LLC | Institution (13F) | 557,172 | 12.32% | 2026-06-30 |
| Vivo Opportunity Fund Holdings, L.P. | 5%+ holder (13G) | 504,645 | 11.15% | 2026-03-31 |
| Vestal Point Capital, LP | Institution (13G, 5%+) | 492,319 | 10.88% | 2026-03-31 |
| Braidwell LP | Institution (13F) | 483,822 | 10.69% | 2026-06-30 |
| Driehaus Capital Management, LLC | Institution (13F) | 433,377 | 9.58% | 2026-06-30 |
| Balyasny Asset Management LP | Institution (13F) | 345,053 | 7.63% | 2026-06-30 |
| Adage Capital Partners GP L.L.C. | Institution (13F) | 335,000 | 7.40% | 2026-06-30 |
Share count 4,524,087 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-04-28 filed 2026-04-30 |
Cormorant Asset Management, |
Sale (S) | 109,331 | $89.50 | 950,000 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DRUG and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →